Pharming Group (OTCMKTS:PHGUF) Hits New 52-Week High - Time to Buy?

Key Points

• Pharming Group's stock reached a new 52-week high of $1.37, showing a significant increase from the previous close of $1.30.
• The company has solid financial ratios, including a quick ratio of 2.07 and a current ratio of 2.79, indicating good liquidity.
• Pharming Group specializes in developing therapies for rare diseases, including treatments for acute hereditary angioedema and PI3K delta syndrome.

Pharming Group NV (OTCMKTS:PHGUF - )'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $1.37 and last traded at $1.37, with a volume of 10000 shares traded. The stock had previously closed at $1.30.

Pharming Group Stock Up 5.4%

The business has a fifty day moving average of $1.17 and a 200 day moving average of $1.03. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.50.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.